Biotech Values

[Titan V]

From an article comparing Viking’s NASH candidate vs Madrigal’s:

Avid biotech traders may be familiar with Madrigal Pharmaceuticals (MDGL), which has more than TRIPLED in value recently, from $15 to $50. At $50, MDGL's market capitalization is just a hair under $600 million. Their main candidate has the same mechanism of action as VK2809, and as Dr. David Bautz has noted (April 2016), looks INFERIOR to VK2809:

However, when taking a closer look at some of the lipid values, it appears that MGL-3196 may not be as effective as VK2809. For triglycerides, of the six cohorts tested with MGL-3196, only one of them was statistically significantly different from the placebo cohort. In comparison, VK2809 was statistically significantly different from placebo in multiple cohorts for triglycerides. In addition, treatment with MGL-3196 resulted in decreases in Lp(A) of between +2.7% to -20%, compared to decreases in Lp(A) from treatment with VK2809 of -15% to -60%. Lastly, treatment with MGL-3196 resulted in decreases in ApoB of -4.9% to -24%, compared to decreases in ApoB from treatment with VK2809 of -10% to -50%. As mentioned earlier, reductions in both Lp(A) and ApoB are associated with increased cardiovascular health, thus the data so far would indicate that VK2809 is superior to MGL-1396 in this regard. [emphasis added]

https://seekingalpha.com/article/4114098-viking-therapeutics-conquering-market-aging-therapies